Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: A meta-analysis

Stroke

Volumn 41, Issue 6, 2010, Pages 1205-1212

  Lee, Meng ^a,b   Hong, Keun Sik ^a,c   Chang, Shen Chih ^a,d   Saver, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c Inje University College of Medicine   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Folic acid; Homocysteine; Meta analysis; Prevention; Stroke

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE;

ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS; STROKE; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 77953133802     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.573410     Document Type: Article

References (50)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
2. Curro M, Condello S, Caccamo D, Ientile R. Homocysteine-induced toxicity increases TG2 expression in neuro2a cells. Amino Acids. 2009; 36:725-730.
3. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050. (Pubitemid 128753793)
4. Ridker PM, Manson JE, Buring JE, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817-1821.
5. Khan U, Crossley C, Kalra L, Rudd A, Markus HS. Homocysteine and its relationship to stroke subtypes in a UK black population: the South London ethnicity and stroke study. Stroke. 2008;39:2943-2949.
6. Iso H, Moriyama Y, Sato S, Kitamura A, Shimamoto T. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation. 2004;109:2766-2772.
7. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
8. Jacob RA, Wu MM, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr. 1994;124:1072-1080.
9. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82:806-812.
10. Till U, Rohl P, Jentsch A, Till H, Muller A, Riezler R. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis. 2005;181:131-135.
11. Hodis HN, Mack WJ, Dustin L, Selzer RH. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke. 2009;40:730-736.
12. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Med Assoc. 2006;296:2720-2726.
13. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369:1876-1882.
14. Al-Delaimy WK, Rexrode KM, Hu FB, Albert CM, Manson JE. Folate intake and risk of stroke among women. Stroke. 2004;35:1259-1263.
15. He K, Merchant A, Rimm EB, Willett WC, Ascherio A. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 2004;35:169-174.
16. Larsson SC, Mannisto S, Virtanen MJ, Virtamo J. Folate, vitamin B6, vitamin B12, and methionine intakes and risk of stroke subtypes in male smokers. Am J Epidemiol. 2008;167:954-961.
17. Albert CM, Cook NR, Gaziano JM, Zaharris E, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. J Am Med Assoc. 2008;299:2027-2036.
18. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nyagrd O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. J Am Med Assoc. 2008;300:795-804.
19. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. J Am Med Assoc. 2007;298:1163-1170.
20. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896-1900.
21. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
23. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. West Sussex: Cochrane Collaboration and John Wiley & Sons Ltd; 2008.
24. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985;41:55-68.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
26. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-1055.
27. Baker F, Picton D, Blackwood S, Brown MJ. Blind comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation. 2002;106(suppl 2): 741S. Abstract.
28. Schnyder G, Roffi M, Flammer Y, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. J Am Med Assoc. 2002;288:973-979.
29. Righetti M, Ferrario GM, Milani S, Sessa A. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit. 2003;9:PI37-PI42.
30. Lange H, Suryapranata H, De Luca G, Dambrink JHE. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-2681. (Pubitemid 38788002)
31. Vianna AC, Mocelin AJ, Matsuo T, Matni AM. Uremic hyperhomocys-teinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int. 2007;11:210-216.
32. Potena L, Grigioni F, Masetti M, Branzi A. Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study. Transplantation. 2008;85:1146-1150.
33. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;41:2105-2113.
34. Mark SD, Wang W, Fraumeni JF Jr, Li JY, Taylor PR, Wang GQ, Guo W, Dawsey SD, Li B, Blot WJ. Lowered risks of hypertension and cerebro-vascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol. 1996;143:658 - 664.
35. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, van Veldhuisen DJ. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol. 2004;93:175-179.
36. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: results of the GOES extension study. Heart. 2005;91:1213-1214.
37. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. J Am Med Assoc. 2004;291:565-575.
38. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004;15:420-426.
39. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
40. Lonn E, HOPE 2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
41. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379-386.
42. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Walker R, McNeil JJ. Cardiovascular morbidity and mortality in the atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47:1108-1116.
43. Collins R, Armitage J. Study of the effectiveness of additional reductions in cholesterol and homocysteine. 2008:http://directnews. americanheart. org/extras/pdfs/search-slides.pdf Accessed June 1, 2009.
44. Shirodaria C, Antoniades C, Lee J, Moat SJ. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation. 2007;115:2262-2270.
45. Yang Q, Botto LD, Erickson JD, Friedman JM. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation. 2006;113:1335-1343.
46. Mikael LG, Genest J Jr, Rozen R. Elevated homocysteine reduces apo-lipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res. 2006;98:564-571.
47. Liao D, Tan H, Hui R, Wang H. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res. 2006;99:598-606.
48. Qujeq D, Omran TS, Hosini L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem. 2001;34:97-101. (Pubitemid 32322699)
49. Sanossian N, Saver JL, Navab M, Ovbiagele B. High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke. 2007;38:1104-1109.
50. Nissen SE, Nicholls SJ, Sipahi I, Tuzcu EM; ASTEROID investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc. 2006;295:1556-1565.